Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

(2008) M. Crump et al.   ANNALS OF ONCOLOGY

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

(2008) A. Ferrajoli et al.   BLOOD

Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1

(2008) D. H. Shin et al.   BLOOD

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B

(2008) Sonali M. Smith et al.   BRITISH JOURNAL OF HAEMATOLOGY

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma

(2008) Morton Coleman et al.   LEUKEMIA & LYMPHOMA

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

(2008) Tuomas Tammela et al.   NATURE

High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial

(2007) Danielle Canioni et al.   JOURNAL OF CLINICAL ONCOLOGY